Page last updated: 2024-11-11

resiniferatoxin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

resiniferatoxin: phorbol related diterpene ester; potent agonist of vanilloid TRPV1 receptors [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

resiniferatoxin : A heteropentacyclic compound found in Euphorbia poissonii with molecular formula C37H40O9. It is an agonist of the transient receptor potential cation channel subfamily V member 1 (TrpV1). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
EuphorbiagenusA large plant genus of the family EUPHORBIACEAE, order Euphorbiales, subclass Rosidae. They have a milky sap and a female flower consisting of a single pistil surrounded by numerous male flowers of one stamen each. Euphorbia hirta is rarely called milkweed but that name is normally used for ASCLEPIAS.[MeSH]EuphorbiaceaeThe spurge family of flowering plants in the order Malpighiales. The family consists of annual and perennial herbs and woody shrubs or trees. Members contain securinine.[MeSH]
Euphorbia poissoniispecies[no description available]EuphorbiaceaeThe spurge family of flowering plants in the order Malpighiales. The family consists of annual and perennial herbs and woody shrubs or trees. Members contain securinine.[MeSH]

Cross-References

ID SourceID
PubMed CID5702546
CHEMBL ID448382
CHEMBL ID17976
CHEBI ID8809
SCHEMBL ID17792942
MeSH IDM0082557

Synonyms (43)

Synonym
13-benzyl-6-hydroxy-15-isopropenyl-4,17-dimethyl-5-oxo-(1r,2s,6r,10s,11r,13s,15r,17r)-12,14,18-trioxapentacyclo[11.4.1.01,10.02,6.011,15]octadeca-3,8-dien-8-ylmethyl 2-(4-hydroxy-3-methoxyphenyl)acetate
CHEMBL448382 ,
resinferatoxin
resiniferatoxin(rtx)
(4-hydroxy-3-methoxy-phenyl)-acetic acid (2r,3s,3ar,5r,5ar,8br,11ar)-3b-benzyloxy-11a-hydroxy-5a-isopropenyl-2,4-dimethyl-1-oxo-1,3a,3b,4,5,5a,8a,8b,11,11a-decahydro-6,8-dioxa-indeno[5,4-e]azulen-10-ylmethyl ester
13-benzyl-6-hydroxy-15-isopropenyl-4,17-dimethyl-5-oxo-(2s,6r,10s,11r,15r,17r)-12,14,18-trioxapentacyclo[11.4.1.01,10.02,6.011,15]octadeca-3,8-dien-8-ylmethyl 2-(4-hydroxy-3-methoxyphenyl)acetate
13-benzyl-6-hydroxy-15-isopropenyl-4,17-dimethyl-5-oxo-(1r,2s,6r,10s,11r,15r,17r)-12,14,18-trioxapentacyclo[11.4.1.01,10.02,6.011,15]octadeca-3,8-dien-8-ylmethyl 2-(4-hydroxy-3-methoxyphenyl)acetate
bdbm50052442
reciniferatoxin
6,7-deepoxy-6,7-didehydro-5-deoxy-21-dephenyl-21-(phenylmethyl)daphnetoxin 20-(3-hydroxy-5-methoxybenzeneacetate)
benzeneacetic acid, 4-hydroxy-3-methoxy-, ((2s,3ar,3bs,6ar,9ar,9br,10r,11ar)-3a,3b,6,6a,9a,10,11,11a-octahydro-6a-hydroxy-8,10-dimethyl-11a-(1-methylethenyl)-7-oxo-2-(phenylmethyl)-7h-2,9b-epoxyazuleno(5,4-e)-1,3-benzodioxol-5-yl)methyl ester
resiniferatoxin
rtx ,
57444-62-9
NCGC00162396-01
gtpl2491
CHEMBL17976
a5o6p1ul4i ,
who 11485
resiniferatoxin [usan]
unii-a5o6p1ul4i
[3h]resiniferatoxin
gtpl4091
[(2s,3ar,3bs,6ar,9ar,9br,10r,11ar)-2-benzyl-6a-hydroxy-8,10-dimethyl-11a-(prop-1-en-2-yl)-7-oxo-3a,6,6a,7,9a,10,11,11a-octahydro-3bh-2,9b-epoxyazuleno[5,4-e]-1,3-benzodioxol-5-yl]methyl 2-(4-hydroxy-3-methoxyphenyl)acetate
resiniferatoxin [who-dd]
(+)-resiniferatoxin
mtx-71
resiniferatoxin [inn]
mtx-071
lopain
CHEBI:8809
[(2s,3ar,3bs,6ar,9ar,9br,10r,11ar)-2-benzyl-6a-hydroxy-8,10-dimethyl-7-oxo-11a-(prop-1-en-2-yl)-3a,6,6a,7,9a,10,11,11a-octahydro-3bh-2,9b-epoxyazuleno[4',5':5,6]benzo[1,2-d][1,3]dioxol-5-yl]methyl (4-hydroxy-3-methoxyphenyl)acetate
4-hydroxy-3-methoxy-[(2s,3ar,3bs,6ar,9ar,9br,10r,11ar) -3a,3b,6,6a,9a,10,11,11a-octahydro-6a-hydroxy-8,10-dimethyl-11a-(1-methylethenyl)-7-oxo-2-(phenylmethyl)-7h-2,9b-epoxyazuleno[5,4-e]-1,3-benzodioxol-5-yl]benzeneacetate
AKOS024456409
SCHEMBL17792942
[(2s,3ar,3bs,6ar,9ar,9br,10r,11ar)-2-benzyl-6a-hydroxy-8,10-dimethyl-7-oxo-11a-(prop-1-en-2-yl)-3a,6,6a,7,9a,10,11,11a-octahydro-2h,3bh-2,9b-epoxyazuleno[4',5':5,6]benzo[1,2-d][1,3]dioxol-5-yl]methyl (4-hydroxy-3-methoxyphenyl)acetate
DTXSID00894764
Q3277888
4-hydroxy-3-methoxy-benzeneacetic acid, [(2s,3ar,3bs,6ar,9ar,9br,10r,11ar)-3a,3b,6,6a,9a,10,11,11a-octahydro-6a-hydroxy-8,10-dimethyl-11a-(1-methylethenyl)-7-oxo-2-(phenylmethyl)-7h-2,9b-epoxyazuleno[5,4-e]-1,3-benzodioxol-5-yl]methyl ester
DB06515
[(1r,2r,6r,10s,11r,13s,15r,17r)-13-benzyl-6-hydroxy-4,17-dimethyl-5-oxo-15-prop-1-en-2-yl-12,14,18-trioxapentacyclo[11.4.1.01,10.02,6.011,15]octadeca-3,8-dien-8-yl]methyl 2-(4-hydroxy-3-methoxyphenyl)acetate
HY-N2333
CS-0021288

Research Excerpts

Overview

Resiniferatoxin (RTX) is a potent capsaicin analog used as a drug for experimental therapy to treat neurogenic disorders associated with enhanced nociceptive transmission. It is an ultrapotent agonist of transient receptor potential vanilloid subtype-1 (TRPV1) receptors.

ExcerptReferenceRelevance
"Resiniferatoxin (RTX) is a metabolite extracted from Euphorbia resinifera. "( Resiniferatoxin Hampers the Nocifensive Response of Caenorhabditis elegans to Noxious Heat, and Pathway Analysis Revealed that the Wnt Signaling Pathway is Involved.
Arvanitis, DN; Beaudry, F; Nkambeu, B; Salem, JB, 2022
)
3.61
"Resiniferatoxin (RTX) is a potent capsaicin analog used as a drug for experimental therapy to treat neurogenic disorders associated with enhanced nociceptive transmission, including lower urinary tract symptoms. "( Molecular Influence of Resiniferatoxin on the Urinary Bladder Wall Based on Differential Gene Expression Profiling.
Bossowska, A; Lepiarczyk, E; Majewska, M; Majewski, MK; Paukszto, Ł; Wiszpolska, M; Łopieńska-Biernat, E, 2023
)
2.66
"Resiniferatoxin (RTX) is an ultrapotent agonist of transient receptor potential vanilloid subtype-1 (TRPV1) receptors."( Changes in TRPV1 Receptor, CGRP, and BDNF Expression in Rat Dorsal Root Ganglion with Resiniferatoxin-Induced Neuropathic Pain: Modulation by Pulsed Radiofrequency Applied to the Sciatic Nerve.
Hidaka, K; Koshida, T; Kurogi, M; Maruta, T; Nemoto, T; Takeya, R; Tanaka, N; Tsuneyoshi, I; Yanagita, T, 2023
)
1.85
"Resiniferatoxin (RTX) is an ultrapotent capsaicin analog with a unique spectrum of pharmacological actions. "( Resiniferatoxin: Nature's Precision Medicine to Silence TRPV1-Positive Afferents.
Szallasi, A, 2023
)
3.8
"Resiniferatoxin (RTX) is an ultrapotent synthetic TRPV1 agonist and many different administration routes are available for different mechanisms and different effects."( Antiallodynic effect of intrathecal resiniferatoxin on neuropathic pain model of chronic constriction injury.
Martins de Andrade, AL; Parisi, JR; Silva, ML; Torres Silva, JR, 2017
)
1.45
"Resiniferatoxin (RTX) is a very potent and selective TRPV1 agonist and is a promising candidate for treating many types of pain."( Pain control through selective chemo-axotomy of centrally projecting TRPV1+ sensory neurons.
Anderson, EM; Brown, DC; Butman, JA; Caudle, RM; Heiss, JD; Iadarola, MJ; Keller, JM; LaPaglia, DM; Mannes, AJ; Maric, D; Neubert, JK; Raithel, SJ; Rohrs, EL; Sapio, MR, 2018
)
1.2
"Resiniferatoxin (RTX) is an ultrapotent synthetic TRPV1 (transient receptor potential vanilloid subtype 1) agonist with significant initial transient hyperalgesia followed by a prolonged analgesic effect in response to thermal stimulus. "( The effect of clonidine pretreatment on epidural resiniferatoxin in a neuropathic pain rat model.
Choi, SS; Choi, YS; Huh, BK; Hur, WS; Kim, HS; Kim, HZ; Lee, DK; Lee, MG; Lee, MK; Lim, BG, 2015
)
2.11
"Resiniferatoxin (RTX) is a potent analog of capsaicin and activates transient receptor potential (TRP) vanilloid type (TRPV) 1. "( The preventive effect of resiniferatoxin on the development of cold hypersensitivity induced by spinal nerve ligation: involvement of TRPM8.
Ahn, HS; Choi, SS; Kim, JH; Koh, WU; Lee, SK; Leem, JG; Shin, JW; Song, JG; Yoon, HJ, 2016
)
2.18
"Resiniferatoxin (RTX) is an ultra-potent transient receptor potential vanilloid type 1 channel (TRPV1) agonist and can selectively remove TRPV1-expressing primary afferent neurons."( Removing TRPV1-expressing primary afferent neurons potentiates the spinal analgesic effect of delta-opioid agonists on mechano-nociception.
Chen, SR; Pan, HL, 2008
)
1.07
"Resiniferatoxin (RTX) is a TRPV1 agonist that, in high doses, defunctionalises C and Adelta fibres."( A pH-sensitive, neurogenic pathway mediates disease severity in a model of post-ERCP pancreatitis.
Liddle, RA; Noble, MD; Romac, J; Vigna, SR, 2008
)
1.07
"Resiniferatoxin (RTX) is a potent agonist of the transient receptor potential vanilloid 1 channel (TRPV1) found in peripheral nociceptors. "( A high concentration of resiniferatoxin inhibits ion channel function in clonal neuroendocrine cells.
Kissin, I; Strichartz, G; Sugimoto, K, 2008
)
2.1
"Resiniferatoxin (RTX) is an excitotoxic agonist of the vanilloid receptor 1 (VR1), a cation channel protein considered an integrator for nociception."( Brain-derived neurotrophic factor redistribution in the dorsal root ganglia correlates with neuropathic pain inhibition after resiniferatoxin treatment.
Cui, JG; Li, YY; Tender, GC, 2010
)
1.29
"Resiniferatoxin (RTX) is a potent agonist of TRPV1, which possesses unique properties that can be utilized to treat certain modalities of pain. "( Preservation of acute pain and efferent functions following intrathecal resiniferatoxin-induced analgesia in rats.
Bishnoi, M; Bosgraaf, CA; Premkumar, LS, 2011
)
2.04
"Resiniferatoxin (RTX) is a potent synthetic agonist for transient receptor potential vanilloid subtype 1 (TRPV1), which has a selectivity for antinociception. "( The effect of epidural resiniferatoxin in the neuropathic pain rat model.
Choi, SS; Huh, BK; Lee, DK; Lee, M; Lee, MG; Lim, BG,
)
1.88
"Resiniferatoxin (RTX) is an analogue of capsaicin with more than 1,000 times its potency in desensitizing C-fiber bladder afferent neurons. "( Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial.
Chancellor, MB; Erickson, JR; Green, B; Kennelly, M; Kim, JH; O'Leary, M; Rivas, DA; Shenot, PJ; Yoshimura, N, 2003
)
2.13
"Resiniferatoxin (RTX) is a specific C fiber neurotoxin which produces desensitization. "( Role of C afferent fibers and monitoring of intravesical resiniferatoxin therapy for patients with idiopathic detrusor overactivity.
Fujita, O; Inoue, M; Kumon, H; Nose, H; Nozaki, K; Yokoyama, T, 2004
)
2.01
"Resiniferatoxin (RTX) is a vanilloid agonist with a unique spectrum of activities. "( Perineural resiniferatoxin prevents hyperalgesia in a rat model of postoperative pain.
Bradley, EL; Davison, N; Kissin, I, 2005
)
2.16
"Resiniferatoxin (RTX) is an excitotoxic VR1 agonist that causes destruction of VR1-positive neurons."( Selective ablation of nociceptive neurons for elimination of hyperalgesia and neurogenic inflammation.
Iadarola, M; Karai, L; Lonser, RR; Olah, Z; Oldfield, EH; Tender, GC; Walbridge, S, 2005
)
1.05
"Resiniferatoxin is a potent capsaicin analog. "( Physiologic and antinociceptive effects of intrathecal resiniferatoxin in a canine bone cancer model.
Brown, DC; Erin, H; Iadarola, MJ; Laszlo, KJ; Mannes, AJ; Olah, Z; Perkowski, SZ; Shofer, F, 2005
)
2.02
"Resiniferatoxin (RTX) is an ultrapotent capsaicin analog that binds to the transient receptor potential channel, vanilloid subfamily member 1 (TRPV1). "( Perineural resiniferatoxin selectively inhibits inflammatory hyperalgesia.
Abu-Asab, M; Iadarola, MJ; Jenkins, AC; Karai, LJ; Mannes, AJ; Neubert, JK; Zawatski, L, 2008
)
2.18
"Resiniferatoxin is a vanilloid that desensitises nociceptive neurons."( Molecular cloning and expression pattern of rpr-1, a resiniferatoxin-binding, phosphotriesterase-related protein, expressed in rat kidney tubules.
Buchman, VL; Davies, JA; Krylova, O; Ninkina, NN, 1997
)
1.27
"Resiniferatoxin (RTX) is an ultrapotent capsaicin analog that has the significant advantage of being a nonirritant."( Intravesical treatment of overactive bladder.
Fowler, CJ, 2000
)
1.03
"Resiniferatoxin (RTX) is an ultrapotent vanilloid agonist with a unique spectrum of activities different from that of capsaicin."( Selective and long-lasting neural blockade with resiniferatoxin prevents inflammatory pain hypersensitivity.
Bradley, EL; Bright, CA; Kissin, I, 2002
)
1.29
"Resiniferatoxin is an extremely irritant diterpene present in the latex of several members of the genus Euphorbia. "( Resiniferatoxin, a phorbol-related diterpene, acts as an ultrapotent analog of capsaicin, the irritant constituent in red pepper.
Blumberg, PM; Szallasi, A, 1989
)
3.16

Effects

Resiniferatoxin has been shown to increase bladder capacity and improve incontinence in patients with neurogenic and non-neurogenic detrusor overactivity. It has a much higher affinity for TRPV1 than capsaicin, but its ability to modulate excitatory transmission is unclear.

ExcerptReferenceRelevance
"Resiniferatoxin (RTX) has a much higher affinity for TRPV1 than capsaicin, but its ability to modulate excitatory transmission is unclear."( Effect of resiniferatoxin on glutamatergic spontaneous excitatory synaptic transmission in substantia gelatinosa neurons of the adult rat spinal cord.
Fujita, T; Jiang, CY; Kumamoto, E; Liu, T; Nakatsuka, T; Piao, LH; Yue, HY, 2009
)
1.48
"Resiniferatoxin (RTX) has found therapeutic usefulness for the treatment of bladder dysfunction but no data are available on its use as chemotherapeutic agent."( Resiniferatoxin induces death of bladder cancer cells associated with mitochondrial dysfunction and reduces tumor growth in a xenograft mouse model.
Amantini, C; Farfariello, V; Giannantoni, A; Liberati, S; Morelli, MB; Nabissi, M; Santoni, G; Santoni, M; Tomassoni, D, 2014
)
2.57
"Resiniferatoxin (RTX) has a much higher affinity for TRPV1 than capsaicin, but its ability to modulate excitatory transmission is unclear."( Effect of resiniferatoxin on glutamatergic spontaneous excitatory synaptic transmission in substantia gelatinosa neurons of the adult rat spinal cord.
Fujita, T; Jiang, CY; Kumamoto, E; Liu, T; Nakatsuka, T; Piao, LH; Yue, HY, 2009
)
1.48
"Resiniferatoxin has been shown to increase bladder capacity and improve incontinence in patients with neurogenic and non-neurogenic detrusor overactivity."( The overactive bladder: review of current pharmacotherapy in adults. Part 2: treatment options in cases refractory to anticholinergics.
Arya, M; John, J; Khan, MS; Patel, HR; Sahai, A; Singh, R, 2006
)
1.06
"Resiniferatoxin (RTX) has been shown to function as an ultrapotent analog of capsaicin. "( Resiniferatoxin: an ultrapotent selective modulator of capsaicin-sensitive primary afferent neurons.
Blumberg, PM; Joo, F; Szallasi, A; Szallasi, Z; Szolcsanyi, J, 1990
)
3.16

Actions

ExcerptReferenceRelevance
"Resiniferatoxin leads to an increase of paw withdrawal latency to a heat stimulus and caused a mechanical allodynia within 2 weeks. "( Activated Glia Increased the Level of Proinflammatory Cytokines in a Resiniferatoxin-Induced Neuropathic Pain Rat Model.
Gu, X; Lei, Y; Lu, C; Ma, Z; Sun, Y,
)
1.81

Treatment

Pretreatment with resiniferatoxin, an ultrapotent analogue of capsaicin, halved during-discharges and eliminated after-discharged. After-discharge are generated by heat- and mechanosensitive polymodal nociceptors.

ExcerptReferenceRelevance
"Resiniferatoxin, a treatment based on a physiopathological concept (the involvement of C fibers and transient receptor potential vanilloid 1 in the transmission of pain) is undergoing evaluation for interstitial cystitis. "( Resiniferatoxin in the treatment of interstitial cystitis: a systematic review.
Falagas, ME; Iavazzo, C; Mourtzoukou, EG, 2008
)
3.23
"Resiniferatoxin (RTX) treatment or dorsal rhizotomy ablated TRPV1-expressing primary afferents but did not affect TRPV1- and vesicular glutamate transporter-2-expressing dorsal horn neurons."( The glutamatergic nature of TRPV1-expressing neurons in the spinal dorsal horn.
Chen, H; Chen, SR; Pan, HL; Zhou, HY, 2009
)
1.07
"Resiniferatoxin treatment did not alter significantly the degree and time course of allodynia."( Role of primary afferent nerves in allodynia caused by diabetic neuropathy in rats.
Chen, SR; Khan, GM; Pan, HL, 2002
)
1.04
"In resiniferatoxin treated animals (0.3 mg kg-1 subcutaneously) the mean micturition interval and volume, and mean residual volume increased significantly compared to those in controls. "( Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats.
Andersson, KE; Hedlund, P; Lee, T; Streng, T, 2007
)
1.2
"Pretreatment with resiniferatoxin (RTX), an ultrapotent capsaicin analogue known to produce long-lasting desensitization of TRPV1 positive afferents, fully blocked CFA-induced thermal hypersensitivity and abolished the CPP elicited by administration of popliteal fossa lidocaine 24 hrs post-CFA."( Transient inflammation-induced ongoing pain is driven by TRPV1 sensitive afferents.
DeFelice, M; Eyde, N; King, T; Mercado, R; Okun, A; Porreca, F; Ren, J, 2011
)
0.69
"Post-treatment with resiniferatoxin also failed to attenuate allodynia in diabetic rats."( Role of primary afferent nerves in allodynia caused by diabetic neuropathy in rats.
Chen, SR; Khan, GM; Pan, HL, 2002
)
0.63
"Pretreatment with resiniferatoxin, an ultrapotent analogue of capsaicin, halved during-discharges and eliminated after-discharges, suggesting that after-discharges are generated by heat- and mechanosensitive polymodal nociceptors."( Spinal ventral root after-discharges as a pain index: involvement of NK-1 and NMDA receptors.
Honda, M; Ono, H; Tanabe, M; Yamamoto, S, 2006
)
0.66

Toxicity

ExcerptReferenceRelevance
"05 microM RTX, and four in placebo groups), the most commonly reported adverse event was pain during instillation (80."( Prospective, randomized, double-blind study of safety and tolerability of intravesical resiniferatoxin (RTX) in interstitial cystitis (IC).
Camel, M; Chen, TY; Corcos, J; Ponsot, Y; Tu, le M,
)
0.35
" Taken together, these results demonstrate that MPClE is a novel, potent, orally active and safe analgesic drug that targets κ-opioid receptors."( A novel, potent, oral active and safe antinociceptive pyrazole targeting kappa opioid receptors.
Athayde, ML; Boligon, AA; Bonacorso, HG; Calixto, JB; Ferreira, J; Machado, P; Martins, MA; Oliveira, SM; Rosa, F; Rossato, MF; Rubin, MA; Silva, CR; Tonello, R; Trevisan, G; Walker, CI; Zanatta, N, 2013
)
0.39

Dosage Studied

We have compared the actions of the selective neurokinin 1 (NK1) (CP-99,994) and Neurokinin 2 (NK2) (SR-48,968) receptor antagonists against dose-response curves (DRC) induced by intravenously administered substance P (SP) and single dose (intravenous) challenge with resiniferatoxin (RTX)

ExcerptRelevanceReference
" Thus, we have compared the actions of the selective neurokinin 1 (NK1) (CP-99,994) and neurokinin 2 (NK2) (SR-48,968) receptor antagonists against dose-response curves (DRC) induced by intravenously administered substance P (SP), neurokinin A (NKA), neurokinin B (NKB), beta Ala8-NKA (4-10),Sar9-Met(O2)11SP, and single dose (intravenous) challenge with resiniferatoxin (RTX), a capsaicin-like sensory neurotoxin, leukotriene D4 (LTD4) and antigen."( NK1 and NK2 receptors mediate tachykinin and resiniferatoxin-induced bronchospasm in guinea pigs.
Champion, E; Foulon, DM; Jones, TR; Masson, P; Rodger, IW, 1993
)
0.72
" Capsaicin and citric acid gave comparable dose-response curves in the two species."( A comparative study of the effects of citric acid, capsaicin and resiniferatoxin on the cough challenge in guinea-pig and man.
Higgins, KS; Laude, EA; Morice, AH, 1993
)
0.52
" The ideal dosage and treatment interval have not yet been established, and further studies are necessary to confirm our preliminary results."( Intravesical resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord diseases.
Beneforti, P; Lazzeri, M; Spinelli, M; Turini, D; Zanollo, A, 1998
)
0.67
" The final effects of capsaicin depend on the dosage and timing."( Four response stages of capsaicin-sensitive primary afferent neurons to capsaicin and its analog: gastric acid secretion, gastric mucosal damage and protection.
Mózsik, G; Szolcsányi, J; Vincze, A, 2001
)
0.31
" However further studies are necessary and mandatory to confirm our results and to define the exact action mechanism of prolonged infusion of RTX, the dosage and the treatment schedule."( Intravesical infusion of resiniferatoxin by a temporary in situ drug delivery system to treat interstitial cystitis: a pilot study.
Beneforti, P; Giardiello, G; Lazzeri, M; Malaguti, S; Spinelli, M; Turini, D, 2004
)
0.63
") significantly inhibited phenylquinone-evoked writhing movements in mice, but within this dose range no clear dose-response correlation was found."( Analgesic effect of TT-232, a heptapeptide somatostatin analogue, in acute pain models of the rat and the mouse and in streptozotocin-induced diabetic mechanical allodynia.
Almási, R; Bölcskei, K; Börzsei, R; Elekes, K; Helyes, Z; Kéri, G; Petho, G; Pintér, E; Szabó, A; Szolcsányi, J; Szuts, T, 2004
)
0.32
" Therefore, further studies on the optimal dosage and accurate indications for resiniferatoxin instillation are required."( Effect of the intravesical resiniferatoxin instillation evaluated by the ice provocative urodynamic study.
Kang, SW; Kim, YW; Park, CI; Shin, JC; Yang, SC, 2006
)
0.86
" Further validation is required for both treatments, in the form of large randomised controlled trials, before their use can be considered routine, with particular focus on dosing required."( The overactive bladder: review of current pharmacotherapy in adults. Part 2: treatment options in cases refractory to anticholinergics.
Arya, M; John, J; Khan, MS; Patel, HR; Sahai, A; Singh, R, 2006
)
0.33
" Further studies are required to determine the optimal dosing regimes and formulations for individual sub-populations of neurogenic bladder patients and to determine the cost-effectiveness of these interventions."( Improving the global management of the neurogenic bladder patient: part II. Future treatment strategies.
Chartier-Kastler, E; Corcos, J; Denys, P; Everaert, K; Fowler, C; Kalsi, V; Nitti, V; Schulte-Baukloh, H; Schurch, B, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
TRPV1 agonistAn agonist at the transient receptor potential vanilloid 1 (TRPV1).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
neurotoxinA poison that interferes with the functions of the nervous system.
analgesicAn agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (8)

ClassDescription
diterpenoidAny terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
ortho esterAny organooxygen compound that has the general formula RC(OR(1))(OR(2))(OR(3)), where R(1), R(2), R(3) =/= H.
tertiary alpha-hydroxy ketoneAn alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
monomethoxybenzeneCompounds containing a benzene skeleton substituted with one methoxy group.
organic heteropentacyclic compound
carboxylic esterAn ester of a carboxylic acid, R(1)C(=O)OR(2), where R(1) = H or organyl and R(2) = organyl.
enoneAn alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, CruzipainTrypanosoma cruziPotency14.12540.002014.677939.8107AID1476
Microtubule-associated protein tauHomo sapiens (human)Potency19.95260.180013.557439.8107AID1460
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency14.12540.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency25.11890.016525.307841.3999AID602332
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency19.95260.00798.23321,122.0200AID2546
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1346684Human Kv1.5 (Voltage-gated potassium channels)1994Molecular pharmacology, Jun, Volume: 45, Issue:6
Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
AID1346643Rat TRPV1 (Transient Receptor Potential channels)1997Nature, Oct-23, Volume: 389, Issue:6653
The capsaicin receptor: a heat-activated ion channel in the pain pathway.
AID1346690Mouse Kv1.1 (Voltage-gated potassium channels)1994Molecular pharmacology, Jun, Volume: 45, Issue:6
Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
AID1346681Mouse Kv3.1 (Voltage-gated potassium channels)1994Molecular pharmacology, Jun, Volume: 45, Issue:6
Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
AID1346659Mouse Kv1.7 (Voltage-gated potassium channels)1998The Journal of biological chemistry, Mar-06, Volume: 273, Issue:10
Genomic organization, chromosomal localization, tissue distribution, and biophysical characterization of a novel mammalian Shaker-related voltage-gated potassium channel, Kv1.7.
AID1346617Human TRPV1 (Transient Receptor Potential channels)2001European journal of pharmacology, Apr-06, Volume: 417, Issue:1-2
Characterisation using FLIPR of human vanilloid VR1 receptor pharmacology.
AID1346704Rat Kv1.2 (Voltage-gated potassium channels)1994Molecular pharmacology, Jun, Volume: 45, Issue:6
Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
AID1346587Mouse TRPV1 (Transient Receptor Potential channels)2004Neuroscience letters, Nov-03, Volume: 370, Issue:1
Cloning and pharmacological characterization of mouse TRPV1.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (624)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (1.28)18.7374
1990's137 (21.96)18.2507
2000's256 (41.03)29.6817
2010's189 (30.29)24.3611
2020's34 (5.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 58.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index58.21 (24.57)
Research Supply Index6.50 (2.92)
Research Growth Index5.93 (4.65)
Search Engine Demand Index95.88 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (58.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials22 (3.44%)5.53%
Reviews55 (8.61%)6.00%
Case Studies4 (0.63%)4.05%
Observational0 (0.00%)0.25%
Other558 (87.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]